Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Embecta's gross profit for the
three
months ended in Jun. 2026 was MXN2,675 Mil. Embecta's gross profit for the trailing twelve months (TTM) ended in Jun. 2026 was MXN10,799 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Embecta's gross profit for the
three
months ended in Jun. 2026 was MXN2,675 Mil. Embecta's Revenue for the
three
months ended in Jun. 2026 was MXN4,741 Mil. Therefore, Embecta's Gross Margin % for the quarter that ended in Jun. 2026 was 56.42%.
Embecta had a gross margin of 56.42% for the quarter that ended in Jun. 2026 => Durable competitive advantage
During the past 7 years, the highestGross Margin % of Embecta was 70.87%. The lowest was 59.03%. And the median was 68.61%.
Warning Sign:
Embecta Corp gross margin has been in long-term decline. The average rate of decline per year is -2.1%.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Embecta had a gross margin of 56.42% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Embecta Gross Profit Related Terms
Embecta Gross Profit Historical Data
* Premium members only.
The historical data trend for Embecta's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:EMBC vs UTMD, PDEX, KRMD: Gross Profit Comparison
For the Medical Instruments & Supplies subindustry, Embecta's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Embecta Gross Profit vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Embecta's Gross Profit distribution charts can be found below:
* The bar in red indicates where Embecta's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN10,799 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Embecta (MEX:EMBC) has a Gross Profit of MXN10,799 Mil as of Jun. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Embecta and its competitors.
Is Embecta's Gross Profit too high?
Embecta's current Gross Profit is MXN10,799 Mil. Overall, Embecta has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Embecta's Gross Profit compare to UTMD and PDEX?
Embecta's Gross Profit of MXN10,799 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Medical Devices & Instruments company?
A good Gross Profit depends on the Medical Devices & Instruments industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Embecta and its competitors. Embecta's current Gross Profit is MXN10,799 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Embecta stock overvalued right now?
Embecta (MEX:EMBC) has a current Gross Profit of MXN10,799 Mil. The stock's GF Value™ is MXN1,176.20, compared to a current price of MXN497.96 — trading 57.7% below its estimated fair value. The current Gross Profit is MXN10,799 Mil. Embecta's overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Embecta (MEX:EMBC), the current Gross Profit is MXN10,799 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Embecta (MEX:EMBC) Overvalued in 2026?
Based on GuruFocus' analysis, Embecta stock appears to be undervalued.
The current stock price of MXN497.96 is trading 57.7% below its estimated GF Value™ of MXN1,176.20.
Key valuation signals for MEX:EMBC:
Gross Profit: MXN10,799 Mil
GF Value™: MXN1,176.20 vs. price of MXN497.96 (57.7% below fair value)
No single metric tells the full story. See the MEX:EMBC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
51GF Score
Get the complete analysis for MEX:EMBC
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:EMBC has been successfully added to your 
